Triple-negative breast cancer is the form of the disease that has historically been hardest to treat. It has no hormone receptors, no HER2 protein — none of the 'handles' that modern targeted drugs grab on to. For years, chemotherapy has been the only option. Now, researchers at Oregon Health & Science University have published findings on a new molecule called **SU212** that may have found a different way in — by disabling an enzyme cancer cells depend on to fuel their relentless growth.
The results, published in the journal *Cell Reports Medicine* in March 2026, show that in humanised mouse models of triple-negative breast cancer (TNBC), SU212 caused tumours to shrink and significantly slowed the cancer's spread to other tissues.
**The Achilles Heel: An Enzyme Called ENO1**
The key insight behind SU212 is the role of an enzyme called enolase 1, or ENO1. Normal cells produce ENO1 in modest amounts, using it in the metabolic process that converts glucose into energy. But cancer cells — particularly aggressive ones like TNBC — produce ENO1 in dramatically higher quantities, turbocharging their metabolism to support rapid replication and migration.
SU212 was engineered to exploit that difference. It selectively targets and disrupts ENO1, causing the enzyme to break down. Without ENO1 functioning normally, cancer cells lose a critical energy source for growth. In the OHSU experiments, the result was measurable: tumour growth slowed and the cancer's ability to metastasize was curtailed.
What makes this particularly exciting is the potential selectivity of the approach. Because TNBC cells produce far more ENO1 than healthy cells, a drug targeting that enzyme may be able to hit cancer hard while leaving normal tissue relatively unaffected — the same principle behind many of oncology's most successful modern drugs.
**Why Triple-Negative Breast Cancer Is So Difficult to Treat**
Breast cancer is not one disease. It's a family of diseases, differentiated primarily by which protein receptors cells carry on their surface. Most breast cancers test positive for oestrogen receptors, progesterone receptors, or the HER2 protein — and for each, targeted therapies now exist that dramatically improve outcomes.
Triple-negative breast cancer, by definition, tests negative for all three. It accounts for roughly 10–15% of all breast cancer diagnoses but a disproportionately high share of deaths, because it tends to be more aggressive, spreads faster, and responds less well to available treatments. It also disproportionately affects younger women and women of colour.
For TNBC patients, the treatment arsenal has historically been limited to chemotherapy — effective but often harsh and not always durable. In recent years, immunotherapy drugs have extended options for some patients, but meaningful targeted treatments remain limited. SU212 represents a potential new class of approach.
**From Lab to Clinic: The Road Ahead**
The lead researcher, Dr. Sanjay V. Malhotra, co-director of the Center for Experimental Therapeutics at OHSU's Knight Cancer Institute, has been careful to frame the findings as an early but genuinely promising step. SU212 has not yet been tested in humans. Moving to clinical trials will require further preclinical safety testing, FDA approval for trial initiation, and substantial funding.
If SU212's profile holds in human trials — if it is safe, tolerable, and efficacious — it could become one of the first targeted therapies ever approved specifically for TNBC. The researchers also note that ENO1's role in cancer is not limited to TNBC: the enzyme has been identified as a potential target in glioma, pancreatic cancer, and thyroid carcinoma, suggesting broader applications.
For the hundreds of thousands of women diagnosed with triple-negative breast cancer each year, news of a genuinely novel mechanism — one that shrinks tumours by cutting off a cancer cell's energy supply — is the kind of finding that makes the long road of research feel worth it. 🔬
*Sources: OHSU Knight Cancer Institute, SciTechDaily, National Today, Cell Reports Medicine (March 2026)*
